Clinical Trial Update: Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial by the SOLTI Breast Cancer Research Group to predict sensitivity to Olaparib in patients with unresectable locally advanced or metastatic HER2-neg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: COMPLETED